Abezino Tablet 150 mg contains Abemaciclib, a targeted anticancer medicine used mainly in the treatment of certain types of Breast Cancer. It belongs to a class of drugs known as Cyclin‑Dependent Kinase 4 and 6 (CDK4/6) Inhibitors, which work by blocking proteins responsible for cancer cell growth and division.

Abezino Tablet is widely used in patients with hormone receptor-positive (HR+) and HER2-negative advanced or metastatic breast cancer. It can be prescribed either alone or in combination with hormonal therapies such as Fulvestrant or Letrozole. By slowing down the multiplication of cancer cells, this medication helps control the progression of the disease and improves treatment outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each film-coated tablet contains:

• Abemaciclib 150 mg

It is formulated for oral administration and should only be taken under the supervision of a qualified healthcare professional experienced in cancer treatment.

Therapeutic Class

• Antineoplastic (anticancer) agent

• Targeted therapy

• CDK4/6 inhibitor

Indications

Abezino Tablet 150 mg is indicated for the treatment of the following conditions:

1. Hormone receptor-positive, HER2-negative advanced breast cancer.

2. Metastatic breast cancer in adults whose disease has progressed after endocrine therapy.

3. Combination therapy with aromatase inhibitors as an initial endocrine-based treatment in postmenopausal women.

4. Use with Fulvestrant in patients whose cancer progressed following hormonal therapy.

5. Certain cases of early-stage breast cancer with a high risk of recurrence when combined with endocrine therapy.

Doctors determine the appropriate use depending on the patient’s cancer stage, previous treatments, and overall health condition.

Mechanism of Action

Abemaciclib acts by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These enzymes regulate the progression of cells from the G1 phase to the S phase of the cell cycle, which is an essential step in cell division.

In many breast cancers, these kinases become overactive, leading to uncontrolled cell growth. By blocking CDK4 and CDK6, Abemaciclib prevents the phosphorylation of retinoblastoma protein, halting the cell cycle and stopping cancer cells from multiplying. This process slows tumor growth and may lead to cancer cell death.

Dosage and Administration

The dosage of Abezino Tablet should always be determined by an oncologist.

General dosing guidelines include:

• 150 mg twice daily when used in combination with endocrine therapy.

• Taken orally with or without food.

• Tablets should be swallowed whole with water and not crushed or chewed.

• Treatment usually continues until disease progression or unacceptable toxicity occurs.

Dose adjustments may be necessary based on side effects, liver function, or drug interactions.

Possible Side Effects

Like most cancer medicines, Abezino Tablet may cause some adverse effects. Common side effects include:

• Diarrhea

• Nausea and vomiting

• Fatigue or weakness

• Loss of appetite

• Abdominal discomfort

• Decreased white blood cell count (neutropenia)

• Anemia

• Hair thinning

• Increased liver enzyme levels

Patients experiencing severe diarrhea, fever, infection, or unusual bleeding should seek medical attention promptly.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

Before taking Abezino Tablet, certain precautions should be considered:

• Not recommended during pregnancy due to potential risk to the fetus.

• Breastfeeding should be avoided during treatment.

• Regular monitoring of blood counts and liver function tests is necessary.

• Use cautiously in patients with liver impairment.

• Avoid strong CYP3A inhibitors or inducers unless advised by a doctor.

Storage

• Store below 25°C in a cool, dry place.

• Protect from moisture and direct sunlight.

• Keep out of reach of children.